Compare Cytokinetics Inc (CYTK) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Direxion Daily TSLA Bull 2X Shares trades at $10.33 (market cap $3.97B). The key difference: Cytokinetics Inc is far larger — about 2.2× Direxion Daily TSLA Bull 2X Shares's market cap, and Direxion Daily TSLA Bull 2X Shares is more actively traded (38,458,237 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| CYTK | TSLL | |
|---|---|---|
Market Cap | $8.62B | $3.97B |
Volume | 2,594,626 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $87.26 | $23.03 |
52-Week Low | $54.76 | $6.74 |
Typical Hold Time | 19 Days | 15 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.15, down 1.55% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights its sensitivity to Tesla's performance, with a rally noted ahead of the Cybercab event. The ETF's structure amplifies daily returns, making it highly volatile and dependent on Tesla's stock movements.
The outlook for TSLL is tied directly to Tesla's stock volatility and news flow. Investment opportunities exist for traders seeking leveraged exposure to Tesla's upside, but risks include significant volatility decay and the potential for amplified losses. Investors should be cautious of the ETF's daily reset mechanism, which can lead to underperformance over time compared to holding Tesla stock directly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
